INTRODUCTION
============

Pseudoachalasia is a rare esophageal motility disorder that has clinical and diagnostic features consistent with achalasia.[@B1][@B2] The term \"pseudoachalasia\" generally applies to a subgroup of less than 5% of patients presenting with clinical features of achalasia, but in whom an occult malignant tumor is the cause of dysphagia.[@B3] Therefore, most of the malignant tumors associated with secondary achalasia are adenocarcinomas of the esophagogastric (EG) junction, which account for more than 70% of cases.[@B4] The remaining cases involve metastatic disease from the surrounding liver, mediastinum, or biliary cancer. Until now, few cases have been reported to be associated with pancreatic cancer. In this type of pseudoachalasia, the mechanisms proposed to explain the clinical features of pseudoachalasia include a circumferential mechanistic obstruction of the distal esophagus or malignant infiltration that destroys inhibitory neurons within the myenteric plexus of the esophageal wall.[@B5][@B6] In our case, pseudoachalasia was caused by a rare pancreatic cancer beyond the EG junction, and the lesson from that was to not consider the EG area or EG junction tumors alone when diagnosing secondary achalasia.

CASE REPORT
===========

A 47-year-old man was admitted to our hospital with a 3-month history of dysphagia and a resultant 15 kg weight loss in 3 months. The patient did not have any relevant medical history in the previous year, but he had complained of solid food dysphagia at first, which gradually aggravated to liquid food dysphagia. He also experienced intermittent hoarseness. On physical examination, his vital signs were found to be stable and though mild tenderness was found on his epigastrium, there was no palpable mass in the abdomen. To search for the cause of dysphagia, upper endoscopy was performed, revealing some fluid and food contents on the lower esophagus along with a mildly dilated esophagus ([Fig. 1A, B](#F1){ref-type="fig"}); the endoscope met with severe resistance while passing through the EG junction, but the scope could be passed into the stomach ([Fig. 1C](#F1){ref-type="fig"}). On esophageal manometric examination, the pressure of the lower esophageal sphincter was very high, accompanied by a low pressure of the esophageal body and some aperistaltic contractions, which is compatible with achalasia ([Fig. 2](#F2){ref-type="fig"}). Considering the clinical impression of primary achalasia, we injected 0.5 mL of a solution containing 100 IU botulinum toxin (Botox; Allergan, Irvine, CA, USA) mixed with 2 mL normal saline into the EG junction in the 3, 6, 9, and 12 o\'clock directions to relive dysphagia ([Fig. 3](#F3){ref-type="fig"}). Failure to improve symptoms with botulinum toxin led us to perform up to 20 mm through the scope (TTS) esophageal balloon dilatation thrice for 30 seconds each (Cook Tri-Ex; Cook, Duluth, GA, USA) followed by 30 mm TTS ballooning. Considerable resistance to ballooning, which manifested as inefficiency, led us to obtain a chest/abdominal computed tomography (CT) scan to elucidate other possibilities of secondary achalasia. An abdominal CT scan was performed and revealed a 7.5 cm-sized multiple septated cystic pancreatic mass invading the area from the gastric body to the fundus. Minimal omental infiltration was found in the paracardiac area with some ascites in the pelvic cavity, suggesting peritoneal carcinomatosis ([Fig. 4](#F4){ref-type="fig"}). A tumor tissue biopsy confirmed the diagnosis of pancreatic mucinous cyst adenocarcinoma. Although we placed an esophageal stent (uncovered, 5 cm; Taewoong Medical, Seoul, Korea) to relieve dysphagia ([Fig. 5](#F5){ref-type="fig"}), and additionally administered gemcitabine-based chemotherapy (1,000 mg/m^2^ bovine serum albumin; Gemzar, Eli-Lilly, IN, USA), the patient died 5 months later.

DISCUSSION
==========

Pseudoachalasia is an esophageal motility disorder that has clinical, radiographic, and manometric findings indistinguishable from primary achalasia, and is usually associated with EG tumors or other local malignancies. Although the first two cases of secondary, malignancy-induced, achalasia were described by Howarth[@B1] early in 1919, the prevalence of pseudoachalasia is not very rare, and is about 2% to 4% among patients with manometric findings suggestive of achalasia.[@B2][@B3][@B7] Very rarely, a distantly located neoplasm may cause pseudoachalasia through a paraneoplastic process and rarely through malignancy- or chronic illness-associated amyloidosis. Pseudoachalasia associated with pancreatic cancer, as seen in our case, is a very rare manifestation. Based on the current case report, we would like to highlight that when pseudoachalasia is considered in patients complaining of severe weight loss and dysphagia, pancreatic cancer can also be one of the differential diagnoses. The most common mechanism of pseudoachalasia is direct involvement of neoplastic cells in the esophageal myenteric plexus.[@B6] The distinguishing feature of secondary versus primary achalasia is the complete reversal of pathologic motor phenomena following successful therapy of the underlying disorder.[@B8]

Primary malignancy of the EG junction accounts for 54% to 70% of pseudoachalasia cases, with adenocarcinomas of the gastric fundus or distal esophagus being the most commonly implicated tumors.[@B3][@B6][@B8] While many forms of malignancy can metastasize to the esophagus, only 6% of pseudoachalasia cases are secondary to metastatic versus primary disease.[@B4] Differentiation of primary from secondary achalasia has critical implications for patient management because of vastly different approaches for the work-up and treatment of these conditions.

Older age (\>50 years), short clinical history (\<1 year), and significant weight loss (\>15 pounds) in a short period of time are usually considered suggestive of malignancy-associated pseudoachalasia.[@B9][@B10] Although combined clinical criteria can provide a highly sensitive test for secondary achalasia, the low prevalence and similar clinical and radiological presentations of secondary achalasia make these criteria inaccurate in predicting the disease.[@B10]

The presence of a dilated esophagus on barium swallow examination, and a dilated esophagus filled with food materials and with a tapered narrowing on endoscopy are common findings in both primary and secondary achalasia, which are very hard to differentiate based on these examinations. The most sensitive test to diagnose primary achalasia is esophageal manometry, typically with incomplete lower esophageal sphincter relaxation and complete aperistalsis of the esophageal body. The presence of peristalsis in some swallows should itself raise the suspicion of pseudoachalasia, but in some cases like ours, complete aperistalsis of the esophageal body cannot discriminate between primary and secondary achalasia at all. Instead, endoscopic ultrasound and CT are useful diagnostic tools to differentiate between secondary and primary achalasia. This was ambiguous in our case as well, but the CT scan clearly suggested pseudoachalasia. A recent study showed that distal esophageal wall thickening that is nodular or lobulated and asymmetric; a soft-tissue mass at the EG junction; mediastinal lymphadenopathy; and pulmonary, hepatic, or osseous metastases are findings that point to secondary achalasia.[@B11] In our case, CT scans showed a mediastinal mass originating from the pancreas that compressed the EG junction; invaded the spleen and both diaphragmatic crus; and encased the celiac trunk, common hepatic arteries, splenic vein, and left adrenal gland. Since CT scans are not routinely used in the assessment of primary achalasia,[@B12][@B13] it is very difficult to distinguish primary achalasia from pseudoachalasia using routine examinations; however, we would like to suggest that in patients showing a weak response to conventional achalasia treatment, CT scans should be mandatory in order to exclude the second clinical condition.[@B14]

In conclusion, we should pay attention to malignant tumors as a cause of secondary achalasia because of the increasing incidence of malignancies. The failure of conventional treatment for primary achalasia, such as medication, botulinum toxin injection, and pneumatic dilation, might suggest the possibility of secondary achalasia. Furthermore, in addition to EG junction malignancy, GI malignancies at other sites should be included in the differential diagnosis. In the literature, only four cases of pseudoachalasia in pancreatic cancer patients have been described until now.[@B15][@B16][@B17][@B18] Their mean age was 64.75 years, the clinical history was 5.75 months, and weight loss was prominent, typically around 14 kg. The CT scan showed invasion of the EG junction. In this article, we report a case of pseudoachalasia in a middle-aged man with recent onset of symptoms and with substantial weight loss. Esophageal manometric findings typical of achalasia were observed. An abdominal CT scan showed typical features, suggesting secondary achalasia. Although very rare, pseudoachalasia is a clinical condition that should be considered in the differential diagnosis of achalasia in patients presenting with dysphagia. It should be remembered that tumors outside the EG area could also be responsible for secondary achalasia.
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![Esophagoscopic finding suggestive of primary achalasia. A dilated esophagus filled with liquid and some solid foods is visible (A, B), which is compatible with the findings of primary achalasia. There was no evidence of extrinsic compression or any cardiac lesion on retroversion of endoscopy (C).](ce-48-328-g001){#F1}

![Esophageal manometry findings suggestive of primary achalasia. Manometry shows a total absence of peristalsis in the body of the esophagus (vacant arrow) and a hypertonic lower esophageal sphincter with incomplete relaxation (filled arrow).](ce-48-328-g002){#F2}

![Botulinum toxin injection therapy to relieve achalasia. In total, 4 mL of botulinum toxin was injected at four points in the esophagogastric junction with 1 mL injected at each point. The photographs show the condition of the esophagogastric junction before (A) and after (B) the botulinum toxin injections.](ce-48-328-g003){#F3}

![Abdominal and pelvic computed tomography findings showing a huge mass extending into the gastric fundus. An approximately 7.5-cm sized irregular infiltrative solid mass with multiple septated cystic portions originating from the pancreas had invaded the gastric body and extended to the gastric fundus (arrow).](ce-48-328-g004){#F4}

![Esophageal stent insertion to relieve dysphagia of secondary achalasia. Endoscopic image of an esophageal stent (uncovered, 5 cm; Taewoong Medical) placed across the esophagogastric junction into the proximal stomach.](ce-48-328-g005){#F5}
